Pharmaceutical Technology
SEPTEMBER 15, 2022
Regeneron’s windfall of $16.1bn in revenue for the year was largely due to its Covid-19 monoclonal antibody therapy, REGEN-COV; due to its ineffectiveness against the Omicron variant, however, its success is expected to be short-lived. Moderna’s Covid-19 vaccine, Spikevax, also contributed to the company’s $18.5bn in revenue for the year.
Pharmaceutical Technology
DECEMBER 20, 2022
The growing competition from generic drugs presents challenges for the top 20 players placing pressure on drug prices. The FDA also awarded priority review for Eli Lilly’s donanemab, a monoclonal antibody for Alzheimer’s disease, in August 2022, and the company expects approval by February 2023. trillion in Q2 2022 to $3.14
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
OCTOBER 28, 2021
Antibody therapies have also been developed for use in non-hospitalised patients, but these still have to be administered by infusion in a clinic. Merck is also testing its drug for prevention of COVID-19 in patients exposed to SARS-CoV-2, and analysts said that could increase sales projections if the results are positive.
Camargo
MAY 10, 2021
the Center’s chief of medical oncology, In it, they laid out their analysis of accelerated approvals for 35 oncology indications for anti-programmed death ligand 1 antibodies and reported that for 10 of the 35 indications, the confirmatory trials failed to show a benefit. The meeting was prompted by a publication by Richard Pazdur, M.D.,
XTalks
FEBRUARY 8, 2021
In order to fact-check some of these misconceptions, the US Food and Drug Administration (FDA) recently hosted a webinar on biosimilar and interchangeable biological products to help healthcare professionals understand more about these treatment options. Biosimilars are the “generic” drugs of the biopharma world.
The Pharma Data
MAY 7, 2021
EU regulator begins real-time review of GSK-Vir COVID-19 antibody drug ( Reuters ) ( Press ). Two drug makers, two commercial launches — with divergent results ( STAT ). Gillibrand touts legislation to lower drug costs: This idea ‘is deeply bipartisan’ ( The Hill ).
XTalks
FEBRUARY 5, 2024
Why it did so well: Darzalex was the first human anti-CD38 monoclonal antibody approved by the FDA for multiple myeloma. Despite Bristol Myers Squibb’s Revlimid remaining the top-selling drug for multiple myeloma for several years now, Darzalex is not too far behind. The worldwide net trade sales of Darzalex were $2.26
Expert insights. Personalized for you.
272 
Let's personalize your content